42221-50-1

Basic information

• Product Name: 3,4,5-trichloro-benzoyl chloride
• Synonyms: 3,4,5-trichloro-benzoyl chloride
• CAS NO: 42221-50-1
• Molecular Weight: 243.904
• Mol File: 42221-50-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 3,4,5-trichloro-benzoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4,5-trichloro-benzoyl chloride(42221-50-1)
• EPA Substance Registry System: 3,4,5-trichloro-benzoyl chloride(42221-50-1)

Safety Data

• Hazardous Substances Data: 42221-50-1(Hazardous Substances Data)

Upstream product

• 860698-40-4 4-ethoxy-3,5-dinitro-benzoic acid ethyl ester 
• 85365-92-0 3,5-dinitro-4-methoxybenzoic acid 
• 7221-27-4 4-amino-3,5-dinitrobenzoic acid 
• 51-39-8 3,4,5-trichlorobenzoic acid 

Downstream Products

• 99508-32-4 3,4,5-trichloro-benzoic acid amide 
• 104252-63-3 2-(3,4,5-Trichloro-benzoylamino)-pentanedioic acid 
• 131179-85-6 2-[4-(((3,4,5-trichlorobenzoyl)-amino)methyl)phenoxy]-2-methyl propionic acid 
• 102742-64-3 4-Dibutylcarbamoyl-4-(3,4,5-trichloro-benzoylamino)-butyric acid 
• 104252-91-7 3,4,5-Trichloro-N-(2,6-dioxo-tetrahydro-pyran-3-yl)-benzamide 
• 145028-55-3 3,4,5-Trichloro-N-[3-(2,3,5,6-tetrahydro-imidazo[2,1-b]thiazol-6-yl)-phenyl]-benzamide 

Relevant articles and documents

Allosteric Modifiers of Hemoglobin. 1. Design, Synthesis, Testing, and Structure-Allosteric Activity Relationship of Novel Hemoglobin Oxygen Affinity Decreasing Agents

Three isomeric series of 2-(aryloxy)-2-methylpropionic acids were prepared and studied for their ability to decrease the oxygen affinity of human hemoglobin A.The isomeric aryloxy groups included 4-methyl>phenoxy, 4-(arylacetamido)phenoxy, and 4-methyl>phenoxy.A total of 20 compounds were synthesized and tested.Structure-activity relationships are presented.Several of the new compounds were found to be strong allosteric effectors of hemoglobin.The two most active compounds are 2-methyl>phenoxy>-2-methylpropionic acid and the corresponding 3,5-dimethyl derivative.The latter two compounds have been compared to other known potent allosteric effectors in the same assay and show greater activity.Both compounds also exhibit a right shift in the oxygen equilibrium curve when incubated with whole blood.The new compounds may be of interest in clinical or biological areas that require or would benefit from a reversal of depleted oxygen supply (i.e., ischemia, stroke, tumor radiotherapy, blood storage, blood substitutes, etc.).They are also structurally related to several marketed antilipidemic agents.